THERAPY DOSSIER · th-b271c996051b

PJ34

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29852289 ↗2018Mixed findings

Sex differences in the effects of PARP inhibition on microglial phenotypes following neonatal stroke.

MouseIschaemia-reperfusionCerebral (MCAO/stroke)C57BL/6Male and female

Model: Permanent middle cerebral artery occlusion (neonatal ischaemic stroke)

PJ34 reduced lesion size by 78 per cent and CX3CR1-labelled microglial density by 46 per cent at 3 days in male but not female mice. At 8 days, M1-like Iba1/Cox-2 cells fell in PJ34-treated males in the amygdala, while M2-like Iba1/Arg-1 and transitional Arg-1/Cox-2 cells rose in treated females. p…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…